Watch Live

Tweet TWEET

Argan, Sanofi, Stallergenes, Vinci: French Equity Preview

The following is a list of companies whose shares may have unusual price changes in Paris. Stock symbols are in parentheses after company names and prices are from the last close.

France’s benchmark CAC 40 Index (CAC) fell 1.9 percent to 2,926.83. The SBF120 Index decreased 1.9 percent to 2,236.80.

Argan (ARG) : The warehouse owner raised its 2012 forecasts and said it’s studying a “significant” acquisition. Shares fell 2.2 percent to 11.74 euros.

GDF Suez (GSZ) : The utility completed the sale of its G6 Rete Gas unit in Italy to a group including Axa Private Equity, Enel Distribution and F2i infrastructure fund, valued at 772 million euros ($1.02 billion). The shares fell 0.2 percent to 22.40 euros.

Sanofi (SAN FP): The company’s Genzyme unit is unable to meet patient demand for the Fabrazyme drug for Fabry’s disease, the company said in a statement. Cerezyme supply should begin to improve in February, the company said. Shares fell 0.7 percent to 49.01 euros.

Stallergenes SA (GENP) : The pharmaceutical company said Roberto Gradnik would become deputy chief executive officer and the CEO next year, and chairman and CEO Albert Saporta would become non-executive chairman. The shares fell 4.5 percent to 46.50 euros.

Vinci SA (DG) : The builder and Hitachi Ltd. won a contract to build the first phase of the Berjaya Central Park residential and office complex in Kuala Lumpur. The first phase of the contract is worth 76 million euros, Vinci said. Shares fell 1.9 percent to 31.80 euros.

To contact the reporters on this story: James Hertling in Paris at jhertling@bloomberg.net Anne Swardson at aswardson@bloomberg.net

To contact the editor responsible for this story: Vidya Root at vroot@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.